Tempus AI (NASDAQ:TEM) Now Covered by Analysts at Roth Capital

Investment analysts at Roth Capital started coverage on shares of Tempus AI (NASDAQ:TEM) in a report issued on Tuesday, Benzinga reports. The brokerage set a “neutral” rating and a $67.00 price target on the stock. Roth Capital’s price objective would indicate a potential upside of 3.68% from the stock’s current price.

A number of other research firms also recently issued reports on TEM. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Friday, July 31st. HC Wainwright cut their price target on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Wolfe Research assumed coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Stifel Nicolaus lowered their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald began coverage on Tempus AI in a report on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $68.71.

Tempus AI Stock Performance

NASDAQ TEM opened at $64.62 on Tuesday. The business’s 50-day moving average price is $55.90 and its 200 day moving average price is $52.21. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. Tempus AI has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a market capitalization of $11.66 billion, a PE ratio of -44.87 and a beta of 3.72.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the previous year, the business earned ($0.22) EPS. The firm’s revenue was up 21.6% on a year-over-year basis. On average, research analysts predict that Tempus AI will post -1.38 earnings per share for the current year.

Insider Activity

In related news, CEO Ryan Fukushima sold 14,286 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the completion of the sale, the chief executive officer owned 47,420 shares of the company’s stock, valued at approximately $3,319,400. This represents a 23.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the transaction, the chief financial officer owned 106,024 shares in the company, valued at $6,361,440. The trade was a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 1,043,988 shares of company stock worth $56,963,417. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC increased its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after purchasing an additional 381,816 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Tempus AI by 6,379.2% in the second quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock valued at $404,189,000 after buying an additional 6,869,519 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Tempus AI by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock valued at $110,478,000 after buying an additional 141,680 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.